Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 3Primary Myelofibrosis 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Metastatic Pancreatic Ductal Adenocarcinoma 1Leukemia, Myelomonocytic, Chronic 1Gastrointestinal Neoplasms 1Clonal Cytopenia of Undetermined Significance 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 18Surveys and Questionnaires 15Fluorouracil 15Capecitabine 13Leucovorin 12Blood Specimen Collection 11Irinotecan 10Standard of Care 7Cisplatin 7Endoscopic Mucosal Resection 6atezolizumab 5Specimen Handling 5Radiotherapy 5Educational Status 5Drug Therapy 5Docetaxel 5S 1 (combination) 4Radiosurgery 4Nivolumab 4Magnetic Resonance Spectroscopy 4Interviews as Topic 4Gemcitabine 4Everolimus 4Colonoscopy 4Biopsy 4Bevacizumab 4tegafur-gimeracil-oteracil 3pemigatinib 3apatinib 3Remote Patient Monitoring 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Neoplasms × canakinumab × Clear all
NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

Phase 1 Active not recruiting
9 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡